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Abstract (164 words) 
 
Background. The treatment gap for serious mental disorders across low-income countries is estimated to be 89%. The model for 
Mental Health and Development (MHD) offers community-based care for people with mental disorders in eleven low- and 
middle-income countries.  
 
Methods. In Kenya, using a pre-post design, 117 consecutively enrolled participants with schizophrenia-spectrum and bipolar 
disorders were followed-up at 10 and 20 months. Comparison outcomes were drawn from the literature. Costs were analysed from 
societal and health system perspectives. 
 
Results. From the societal perspective, MHD cost Int$ 594 per person in the first year and Int$ 876 over two years. The cost per 
healthy day gained was Int$ 7.96 in the first year and Int$ 1.03 over two years – less than the agricultural minimum wage. The 
cost per DALY averted over two years was Int$ 13.1 and Int$ 727 from the societal and health system perspectives, respectively – 
on par with antiretrovirals for HIV. 
 
Conclusions. MHD achieved increasing returns over time. The model appears cost-effective and equitable, especially over two-
years. Its affordability relies on multi-sectoral participation nationally and internationally. 
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4,309 words 
 
Background 
 
The treatment gap for schizophrenic disorders across 50 low- and middle-income countries has been estimated  at 69% with a 
median treated prevalence rate of 128 per 100 000 population per year, and it rises it 89% in low-income countries, such as Kenya 
(Lora et al., 2012). In Kenya 0.6% of the population report symptoms of psychosis (Jenkins et al., 2012). If symptoms translate to 
a diagnosis, then approximately 230,000 Kenyans are affected by psychosis. Within the public health system, the only source of 
specialist psychiatric care until recently was in hospitals (Kiima and Jenkins, 2010). This is comparable to other African settings, 
such as South Africa, where only 7% of people with severe mental disorders receive specialist mental health care (Williams et al., 
2008). 
 
In 2005, the non-governmental organization (NGO) BasicNeeds introduced its model for Mental Health and Development (MHD) 
to Kenya. MHD is a community-based intervention operating as a public-private partnership. It combines medical care in 
outpatient clinics with social support and economic opportunities through self-help groups.   
 
In 2011 BasicNeeds invested approximately £2 million to deliver MHD across eleven countries to 39,518 people with mental 
illness or epilepsy and their carers (Raja et al., 2012). A study conducted in rural Kenya suggests that MHD is effective at 
improving quality of life, clinical symptoms and functioning (Lund et al., 2012). The aim of the present paper is to examine 
MHD’s cost-effectiveness compared with usual care. 
 
 
Methods 
 
Data were collected from July 2009 to May 2011 in Nyeri and Meru districts. Using a pre-post design, measures of wellbeing, 
service use and economic impact were administered at baseline, 10 and 20 months. Comparison results were drawn from the 
literature, outside the primary setting. We reviewed prospective and retrospective cohort studies of the natural course of 
schizophrenia and bipolar disorder from low-income countries (Thirthalli et al., 2009, Haro et al., 2011, Ran et al., 2001) and 
selected one from Ethiopia (Kebede et al., 2005) for being closest in context. 
 
The Kenyan sample was 117 adults (18 years and older) with schizophrenia-spectrum and bipolar disorders sequentially enrolled 
in MHD.  
 
Intervention 
MHD comprises five modules: capacity-building; community mental health; livelihoods; research; and collaboration (Raja et al., 
2012). 
  
Non-governmental partners were CARITAS in Nyeri and a national women’s organization, Maendeleo ya Wanawako, in Meru. 
The Ministry of Health provided psychiatric nurses and health facilities. The Ministry of Gender Children and Social Services 
registered self-help groups and coordinated training in livelihoods and farming practices with the Ministry of Agriculture, 
Livestock and Fisheries.  
 
Activities: 
Consultation meetings were held for affected persons, caregivers and other stakeholders to discuss mental health symptoms and 
sensitize the public to mental illness and ways of addressing it. This was the first step to case-finding and mobilization. 
 
New outpatient mental health clinics were opened, operated by a psychiatric nurse or a primary care provider with training in 
mental health care and a community health worker (CHW), whose role was to accompany patients to the clinic, translate in case 
of language problems and provide aftercare support through home visits. Clinics ran daily at the district hospital and monthly in 
health centres and dispensaries. Users paid standard public health fees of Int$ 0.5 (Ksh 20) per visit. The primary treatment 
available through these clinics was psychiatric medicines and basic counselling. Clinicians prescribed first-generation 
antipsychotics (fluphenazine, haloperidol and chlorpromazine) in combination with trihexyphenidyl (brand Artane) to control 
extra-pyramidal symptoms for schizophrenia-spectrum disorders, and carbamazepine for bipolar disorder. Tricylic antidepressants 
(imimpramine, amitriptaline) were also available to treat co-occurring mood disorders. 
 
Home visits were made by CHWs monthly in Nyeri and quarterly in Meru to assess: a) medication adherence and side-effects; b) 
family and community integration; c) particular needs; and d) programme data. Patients with particular needs received additional 
visits. 
 
Self-help groups were established to offer psychosocial support and be a vehicle for livelihoods and self-advocacy. Groups 
averaged 15-25 people in size, met once a month and contained both users and carers, facilitated initially by a CHW. Examples of 
livelihood activities included drought-resistant farming and making detergent. 
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BasicNeeds and partners collaborated to deliver training, lasting 1-2 days in: 1) group formation and management; 2) book-
keeping; 3) livelihoods; 4) advocacy; and  5) group dynamics. In addition, external training was offered on: 1) financial literacy; 
and 2) livelihood skills.  
 
Mental Health Action Groups met quarterly in each district to address issues raised by users and carers, for example, a rape, 
medicine shortages, and user fees. Action Groups had 7-10 members including lawyers, priests, a user, a carer, a youth 
representative and the MHD coordinator.  
 
Usual Care  
In the absence of a local comparison group, ‘usual care’ was characterized by obtaining evidence from the literature, using a 
prospective cohort study from rural Ethiopia (Kebede et al., 2005), observing the natural course of 307 individuals with 
schizophrenia over four years. At baseline, 89% of the sample were treatment-naïve, and  at follow-up patients had received a 
“first-generation” neuroleptic 28% of the intervening time. Follow-up treatment was measured on a monthly basis using clinical 
files completed by psychiatric nurses for those showing up to treatment. 
 
One- and two-year time-frames were adopted for analysis, because outcomes in the comparison study were annual. Mean time to 
follow-up was 294 days (sd 36) and 593 days (sd 39), so costs and outcomes were annualized based on linear trends, as done 
elsewhere (McCrone et al., 2004). 
 
Costs 
Primary analysis was undertaken from the societal perspective and secondary analysis from a health system perspective. Kenyan 
shillings were converted at a rate of 42.48 per international dollar. 
 
Government costs were drawn from World Health Organization unit cost estimates for Kenya. In the absence of adherence data, 
attendance at monthly outpatient clinics was assumed to be perfect (the conservative, high-cost estimate). 
 
NGO costs were derived from bottom-up patient-level data and top-down analysis. Costs associated with the MHD research 
module and national advocacy were excluded, since they do not affect clinical outcomes. Set-up costs were also excluded. Present 
value (December 2011) of capital costs was calculated using linear discounting with the Central Bank of Kenya interest rate of 
7%.  
 
User costs were measured with an adaptation of the Economic Status Instrument, a multiple choice and short-answer interview 
piloted in India.(Murthy et al., 2005) Baseline costs were used to estimate usual care. Direct or out-of-pocket fees included: 1) 
hospitalization; 2) outpatient treatment; 3) medicines; and 4) traditional healing. Resource use was measured using anintervention 
checklist designed for this study. 
 
Indirect costs were aggregated from time spent in treatment and unpaid care, offset against productivity gains and losses. 
Productivity was valued using a variant of the human capital approach:(Su et al., 2007) paid and unpaid productive work were 
valued equally at minimum wage for an unskilled agricultural worker: Int$ 98.0 (3,765 Ksh) per month, full-time. This approach 
ensures gender equality and accounts for the non-wage economy. Productivity in the comparison was held constant at baseline 
levels.  
 
Diagnosis, Treatment and Outcomes 
Primary diagnosis was made by the treating clinician – either a psychiatric nurse or a clinical officer for health (primary care 
provider) who received top-up training on identifying and treating mental disorders. Diagnoses were made at all three time periods 
based on clinical presentation. When diagnosis varied between time periods, the treating clinician identified the primary diagnosis 
after the study’s completion. Individuals with comorbid epilepsy were excluded from analysis. No information was gathered on 
illness onset. 
 
At baseline, patients at the clinic received a mean of 2.4 medicines (sd 0.66, range 1-4). The majority of patients (88.9%, n=104) 
were prescribed an atypical antipsychotic. The most commonly prescribed antispychotic was chlorpromazine (prescribed to 70.2% 
of patients, n=82), followed by injectable fluphenazine (42.7%, n=50) and haloperidol (18%, n=22). Those not receiving an 
antipsychotic were prescribed either a tricyclic (13.7%, n=16) or carbamazepine (5.1%, n=6). 
 
The primary outcome was the General Health Questionnaire (GHQ-12) and the secondary outcome was the WHO Quality of Life 
questionnaire (WHOQOL-Bref). Both were interview-administered, because of illiteracy.  
 
GHQ-12 was scored from 0-12 with higher scores indicating worse outcomes. The GHQ has been validated in this setting 
previously, with research from Kenya (Njenga, 2000, Jenkins et al., 2013) suggesting a cut-off of 3 (0-2 healthy, 3-12 sick). This 
is more conservative than literature from Nigeria (Gureje and Obikoya, 1990), but is consistent with Zambia (Chipimo and 
Fylkesnes, 2010), and aligns with recommendations of the tool’s authors (Goldberg et al., 1998). The GHQ is a general measure 
of emotional distress, which we considered important to report in this diagnostically heterogeneous sample. Because of the 
heterogeneity of the sample we chose to use this more general measure rather than disorder-specific clinical outcomes measures 
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such as the PANSS (for schizophrenia) or PHQ-9 (for depression), as it would have been difficult to compare these outcomes 
within the sample.  
 
The WHOQOL Bref (WHOQoL Group, 1998) measures quality of life along four domains: physical health, mental health, social 
relationships, and the environment. Questions are on a Likert scale, resulting in a maximum score of 130. Domains are scored 
from the mean response to selected questions converted to a scale of 100. WHOQOL was used to triangulate GHQ outcomes, but 
not to calculate cost-effectiveness.   
 
The comparison outcome of interest from the Kebede study was the Short-Form 36, scored on a Likert scale across eight domains, 
including mental health (Ware and Sherbourne, 1992). There is good correlation between SF-36 and GHQ, particularly for the 
mental health subscale (Spearman rank 0.73 (McCabe et al., 1996, Kelly et al., 2008)), so we converted SF-36 scores into GHQ. 
 
In the rural Ethiopian cohort, mean SF-36 mental health scores increased in the first year by 9.2% for those with long-standing 
schizophrenia and by 18.3% for those with recent onset disorder. It increased over two years by 12.4% and by 20.3% respectively. 
The sample had 23% recent-onset schizophrenia, so mean SF-36 increase overall was 11.3% in the first year and 14.2% over two 
years, translating to decreases in GHQ-12 of 1.4 and 1.7 points. 
 
To estimate death in the comparison, we multiplied the death rate of a normal Kenyan population with the same age and sex 
distribution, times the standardized mortality ratio of 5.98 for schizophrenia, drawn from the same Ethiopian study (Teferra et al., 
2011). 
 
Statistical Analysis  
Data were analyzed in SPSS 19. 
 
Using the GHQ cut-off of 3, we translated scores into a binary outcome of sickness or health. With GHQ scores on the y-axis and 
time on the x-axis, sick days were defined as  x when y equalled 3.  
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GHQ outcomes were also used to calculate Disability Adjusted Life Years (DALYs), a common measure of disease burden in low-
income setting studies (Rushby and Hanson, 2001). GHQ outcomes were also used to calculate Disability Adjusted Life Years 
(DALYs), a common measure of disease burden in low-income setting studies (Rushby and Hanson, 2001). The term disability in 
the context of DALYs is used broadly to refer to “any short-term or long-term loss of health” (Salomon et al., 2013), and can be 
understood as a synonym for morbidity – which is to say all ill health other than mortality. It is distinct from narrower definitions 
of disability found within the field of psychiatric and physical rehabilitation. Health is measured within the Global Burden of 
Disease methodology – as employed, for example, by the World Health Organization and World Bank –  on the basis of pre-
established health states, each associated with a disability weight (Institute of Health Metrics and Evaluation, 2010).Years Lost to 
Disability (YLD) were calculated using a weight of  0.689 for schizophrenia and psychosis (combining health states for acute and 
residual schizophrenia), and 0.480 for bipolar. Years Lost to Disability (YLD) were calculated using a weight of  0.689 for 
schizophrenia and psychosis (combining health states for acute and residual schizophrenia), and 0.480 for bipolar. No age-
weighting was applied, and DALYs in the second year were discounted. At two years, we assumed those who recovered in the 
first year would have been sick were it not for the intervention.  
 
Cost-effectiveness  
The incremental cost-effectiveness ratio (ICER) comparing costs (C) and effects (E) of an intervention (i) to its comparison (c) is: 
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Ethics 
The study design was approved by the Human Research Ethics Committee of the Faculty of Health Sciences (REC Ref: 098/2009) 
at the University of Cape Town (UCT) and by the National Ethics Review Committee at the Kenya Medical Research Institute 
(KEMRIRES 7/3/1). Participants provided informed consent, or assent and their caregiver consented.  
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Results 
 
The sample  consisted of cases of schizophrenia (n=74, 63%), bipolar disorder (n=26, 22%) and psychosis (other) (n=17, 15%). 
Mean age at baseline was 37 years (sd 11). The population was 55.6% male. One third (31.7%) were educated to less than primary 
level, and 42.7% had primary education. 60.7% were unemployed, and 50.4% were never married. Mean household size was 6, 
and the main source of family income for 64.0% was farming, and for 30.5% casual labour. Median household cash income was 
Ksh 700 (Int$ 18.5) per month.  
 
Resource Use 
Most participants received the main components of the intervention –attending mental health clinics (100%), receiving a diagnosis 
(99%), medication (99%), counselling (97%), home-visits (87%), and enrolling in a self-help group (97%).  
 
Costs 
From the societal perspective, MHD cost Int$ 594 in the first year, as opposed to Int$ 220 for usual care (as measured by baseline 
costs). At two years, the intervention cost Int$ 876 vs Int$ 440 for usual careTable 1). The difference in year two resulted from 
return to productive work. Before the intervention, 92% of costs were borne by the service user, whereas after two years, users 
made savings of Int$ 289 (Figure 1). Most (87% in the first year) direct costs were born by the NGO. Government costs doubled 
during the intervention, as coverage increased; however they remained modest throughout at only 4%-5% of total.  
 
The change in WHOQOL was 18 points out of 130 (13.8%) in 10 months and 27 points (20.7%) over 20 months. Mean 
change across WHOQOL domains was 15.3% in 10 months and 27.5% in 20 months. Greatest change was in the 
environmental domain (plus 21% at 10 months and 34% at 20 months); smallest change was in the physical domain. The 
environmental domain covers seven questions relating to health services, physical environment, money, living conditions, 
transportation, access to information, and leisure. 
 
There was high correlation between WHOQOL and GHQ-12 scores at 10 months (r(103)= -0.723 p<0.001) and 20 
months (r(95) = -0.625, p<0.001), but less so at baseline (r(110) = -0.197, p=.04). Despite low baseline correlation, the 
change in scores remained reasonably correlated at 10 months (r(104)=-0.568, p<0.001) and 20 months (r(94)=-0.334, 
p<0.001), supporting the validity of the GHQ-12 as a measure of quality of life in this population. 
 
Mean GHQ decreased from 8.8 (sd 2.7) to 5.6 (4.3) and 1.8 (2.6) at 10 and 20 months (Table 2). Mean annualized scores 
were 4.6 (sd 3.7) and 1.2 (sd 2.5) at one and two years. Mean change in annualized GHQ was a decrease of 4.2 points (sd 
3.3) in the first year and 8.3 (sd 3.2) over two years.  
 
Mean healthy days gained in the first year of MHD was 55 (sd 88), and 456 (202) over two years. Estimates for  usual 
care were 8 healthy days (sd 48) in the first year and 33 (sd 128) over two years. 
 
 
The change in DALYs between baseline and follow-up was positive in the first year but negative in the second year 
(0.002 and -0.173 DALYs respectively) for those in the MHD group. This means that the health of the group as a whole 
deteriorated over time, despite the intervention, because of deaths. In the comparison group, health deteriorated more over 
two years, as reflected by a greater negative change in DALYs (-1.052 in the first year and -2.250 in two years).  
 
Six people died in the course of study, whereas the expected mortality over two years of a Kenyan population with the 
same age, sex and disease profile was 14. One death occurred in the first ten months and the remainder occurred 
thereafter. Causality was established for two cases as asthma and aggravated assault. 
 
Six subjects (5.1%) were lost to follow-up, because they had moved (n=4), or their whereabouts were unknown (n=2). 
Those who moved did so for jobs (n=2) or to marry (n=1). There was no statistical difference in any variables studied 
between those lost and those retained.  
 
Cost-Effectiveness  
From the societal perspective, the incremental cost of MHD was Int$ 445 per DALY averted in the first year, and Int$ 
13.1 over two years (Table 3). The health system ICER was Int$ 621 per DALY averted in the first year and Int$ 727 over 
two years. The conventional threshold for cost-effectiveness acceptability in low-income settings is per capita GDP per 
DALY averted (Chisholm, 2005) – Int$ 1,920 in Kenya in 2009 –  making MHD cost-effective at one and two years, 
from both the societal and health system perspectives.  
 
Average cost per incremental healthy day from the societal perspective was Int$ 7.96 in the first year and decreased to 
Int$ 1.03 over two years. From the health system perspective, a healthy day cost Int$ 11.11 in the first year, and dropped 
to Int$ 2.54 over two years.  
 
We tested sensitivity relative to: 1) comparison outcomes; 2) government costs; and 3) GHQ cut-off. Scenario 2 (the 
worst-case scenario) reanalysed Ethiopian comparison data according to a person-month analysis (Alem et al., 2009). We 
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multiplied the proportion in remission by percentage time in remission and applied that to days in a year, arriving at an 
estimate of 93 healthy days per year. In addition, cost estimates for government outpatient clinics were tripled to account 
for potentially longer time spent with clinicians in mental health consults than in general health. Scenario 3 adjusted the 
GHQ cut-off, coding anything greater than 2 as sick, whereas previously values between 2 and 3 were healthy.  
 
Scenarios 2 and 3 proved sensitive for healthy days in the first year, but not over two years. DALY results were relatively 
insensitive to both scenarios, as those outcomes appear driven by differences in mortality, rather than remission.  
 
In scenario 2, MHD cost Int$ 23.70 in the first year (table 3),,  but decreased to Int$ 2.92 over two years. The DALY 
ICER in the first year was Int$676 , and over two years Int$784. The increased DALY in two years is driven by mortality, 
which is not accounted for in the same way in the healthy day outcomes. 
 
In scenario 3, healthy days among people in MHD dropped in the first year to 25 days, and over two years to 404 days. 
Comparison outcomes fell to 1 healthy day in the first year and 7 days over two years. The resulting ICERs per healthy 
day were Int$ 15.35 in the first year and Int$ 2.60 in two years, while ICERs per DALY were Int$ 620 in the first year 
and Int$ 726 over two years. 
 
 
 
Conclusions 
 
Our findings suggest that the model for Mental Health and Development achieves increasing returns over time. Positive 
outcomes are driven by a reduction in both morbidity and mortality.  
 
MHD appears cost-effective from both societal and health systems perspectives. Over two years, the cost was 
approximately a dollar per healthy day (Int$ 1.03) from the societal perspective and Int$ 2.54 from the health systems 
perspective – less than a daily farming wage (Int$ 4.2). The incremental cost per DALY averted (year of healthy life) over 
two years was Int$ 13.1 from the societal perspective and Int$ 727 from the health systems perspective.  
 
MHD seems to be reaching the lowest socio-economic groups. According to census data, on average 14.7% of Central 
Kenyans have less than primary education, whereas twice as many (32%) had less than primary education in our sample. 
In addition, economic benefits to service users were substantial: before the intervention, users paid Int$ 53 in direct costs 
and bore Int$ 150 in indirect costs, whereas after two years, the average user made savings of Int$ 289, largely from 
return to productivity.  
 
Despite MHD being cost-effective and equitable, the question remains whether it is affordable. MHD direct costs are 
borne principally (over 80%) by the NGO BasicNeeds, who were financed on this project by UK and European 
governments. Without this external funding, the direct costs of Int $540 per year paid by the NGO would be prohibitive to 
the Kenyan government. To contextualize, the government spend Int$ 15.4 per capita on health across the whole 
population, though the amount per capita on people with severe mental disorders is unknown. The long-term 
sustainability of the MHD intervention relies on continued external funding streams. Further research is necessary to 
determine whether the programme could be sustained if the NGO were to exit the setting, although the existing data 
suggest that the intervention is not self-funding. This is a familiar economic barrier in low-income country contexts 
(McDaid et al., 2008). 
The principle limitation of this study is the absence of a control group. Although we were able to make use of another 
rural East African sample of people with severe mental illness, the Ethiopian sample consisted almost entirely of men and 
did not contain cases with bipolar disorder. A meta-analysis of studies from mostly high-income countries suggests that 
men with schizophrenia have almost equal recovery rates to women, with about one in seven people recovering over time 
(Jääskeläinen et al., 2012). A literature review from low-to-middle income countries, however, suggests that there are sex 
differences in clinical and functional outcomes with psychotic women having poorer prognoses than their male 
counterparts, because of greater stigma, coercion and victimization, contributing to less help-seeking (Chandra et al., 
2012). If this is the case, then comparison outcomes from a mostly male sample would over-estimate recovery, making 
our estimates of MHD outcomes conservative. Nonetheless, the Ethiopian context shares many similarities with that of 
Kenya, including long delays between onset of illness and access to treatment (Bekele et al., 2009). 
 
A further limitation of the study is the use of the GHQ as a measure of outcome. The GHQ is designed as a non-specific 
measure of distress, rather than a measure of psychosis or of disability. It is therefore a limited measure of disability in the 
narrower sense of this term, in that persons with disability can often be asymptomatic. It is best understood in this context 
as a measure of emotional distress (Ogundipe et al., 2014) or a proxy for quality of life (Mosaku et al., 2006), as it has 
been used in other African studies. Future research of this kind could employ the WHODAS 2.0 (World Health 
Organization, 2010), which focuses specifically on disability and has been used to generate utility scores for QALYs. 
 
In addition, we did not collect information on the duration of illness or any other measure of the stage of illness, so it was 
not possible to study the differences in treatment response of those with first episode versus enduring conditions. Finally, 
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our study did not account for partial remission. This distorts outcomes in the first year, since most improvement took 
place above the remission threshold. Further research is needed to determine GHQ thresholds for partial remission in 
Africa.  Despite these limitations, this exploratory study provides valuable economic analysis in a context and for a 
spectrum of illnesses that have not previously been subject to economic evaluation using patient-level data. 
 
From the health system perspective, MHD appears to perform on par with HIV treatments. Highly active anti-retroviral 
therapy (HAART) combined with Directly Observed Treatment Short-Course (DOTS) for TB in Africa costs Int$ 596 to 
Int$ 1,977, versus Int$ 727 to Int$ 784 (best and worst scenarios) for MHD. Furthermore, our data suggest that MHD out-
performs WHO CHOICE models for bipolar disorder (Int$ 2,165 per DALY) (Chisholm et al., 2005), and schizophrenia 
(Int$ 1,670 per DALY) (Chisholm et al., 2008). 
 
Internationally, MHD sits within the context of several models addressing the needs of people with mental illness, in 
particular, Community Based Rehabilitation (CBR) (Helander, 1993), a flagship approach for managing disability. There 
is considerable overlap between the five branches of CBR (health, education, livelihood, social domain, and 
empowerment) and the MHD model, although they have different origins and objectives. What distinguishes the MHD 
model is the strong emphasis on economic empowerment and mobilising local communities to bring its participants into 
the mainstream, originating from the field of development rather than rehabilitation.  
 
The signature elements of MHD are the centrality of user-led advocacy, the equal emphasis on non-medical aspects of 
recovery (especially livelihoods), and partnership with local governments. MHD offers specialised mental health and 
social care in a community setting, addressing a major gap in treatment for a vulnerable population. This study suggests 
that MHD is cost-effective and equitable. However, its affordability relies on external funding. Nationally, the model’s 
sustainability requires multi-sectoral participation from government, civil society and local communities – taking the 
clinic into the community and the community into the clinic. 
 
 
Acknowledgments: Special thanks to Erica Breuer for her contributions to cleaning the data and to Annette Bauer for her 
insights into interpretations of productivity. 
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